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1. INTRODUCTION 
        
1.1. Transglutaminase 2; a multifunctional protein crosslinking enzyme 
Transglutaminase 2 (TG2) is a widely expressed multifaceted enzyme with distinct 
biochemical activities that functions both inside and outside the cell. TG2 was primarily 
described with its transamidation activity which results in postranslational amine 
incorporation into proteins or the formation of proteolytically resistant γ-glutamyl-ε-lysine 
isopeptide bonds between γ-carboxamide group of a protein bound glutamine and ε-amino 
group of a peptide bound lysine residues. TG2, as a transglutaminase, is regulated 
allosterically by calcium and GTP/GDP; that is TG2 is found in open conformation and 
activated when bound to calcium whereas GTP/GDP binding keeps the enzyme in closed 
conformation which in turn results in its inactivation. In addition to its transamidating activity, 
TG2 acts as G protein, protein disulfide isomerase (PDI), protein kinase and DNA hydrolase 
which distinguish TG2 from other members of the family. Besides regulating enzymatic 
activities, TG2 also has certain non-enzymatic roles such as functioning as adaptor protein, 
cell surface adhesion mediator and forming protein scaffolds. 
Since TG2 has such diverse catalytic activities and non-enzymatic functions, it regulates 
plethora of physiological and pathological conditions. In the intracellular environment, TG2 
participates in signaling events and thus regulates cell survival particularly in response to 
hypoxia, oxidative stress, and cell wounding, whereas outside the cell TG2 modulates cell-
ECM adhesion, cell migration and outside-in signaling which are largely linked to its 
interaction with members of the integrin family and fibronectin. Furthermore, TG2 has been 
implicated in wide range of pathological conditions such as tissue fibrosis, inflammation, 
cardiovascular and neurodegenerative diseases, cancer progression and metastasis. The first 
transglutaminase, now designated TG2, was discovered in 1957 as liver enzyme catalyzing 
the incorporation of amines into proteins. Since then, other members of transglutaminase 
family with this activity have been identified from unicellular organisms, invertebrates, fish, 
mammals, and plants. Only one single transglutaminase gene has been found in invertebrates 
whereas nine evolutionary related genes encoding TG1–7, blood coagulation FXIIIa, and the 
inactive epb42 have evolved in vertebrates by successive duplications.  
TG2 is the most extensively studied and most widely distributed member of the 
transglutaminase family. Human TG2 is a 76-kD protein consisting of 687 amino acids 
divided into 4 distinct domains including an N-terminal β-sandwich domain, the catalytic core 
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and two C-terminal β-barrel domains. The catalytically active site of TG2 is composed of 
cysteine 277 (C277), histidine 335 (H335) and aspartate 358 (D358) residues which are 
critical for transamidation activity. Additionally, two conserved tryptophan residues (W241 
and W332) are essential for transamidation activity stabilizing the enzyme-thiol intermediate 
that forms during catalysis. Human TG2 was first cloned and sequenced in 1991. Until now, 
major research groups working in the transglutaminase field used this recombinant TG2 as a 
reference sequence for most of the biochemical, cellular and structural analysis. This 
sequence however, has glycine at position 224 that differs from the TG2 gene in the NCBI, 
Ensembl, ESP (exon sequencing project) and 1KG databases, which show valine at this 
position. According to exon data and also the Uniprot database, TG2 with glycine 224 likely 
arised from a cloning error. All so far available human exon sequencing data show that valine 
is found at position 224 of TG2 which is highly conserved across species and all 
transglutaminases presumed to work in cells. Importantly, Val224 is located in the catalytic 
core domain of the enzyme. 
TG2 is widely expressed in almost all cells and tissues and can be localized in different 
compartments of the cell. Several regulatory elements of human TG2 including retinoic acid 
response elements (1.7 kb upstream of the transcription start site), glucocorticoid response 
element (1399 bp upstream), an interleukin 6 response element (1190 bp upstream), TGF- β1 
response element (900 bp upstream), two AP2-like response elements (634 bp and 183 bp 
upstream of the start site), hypoxia response element (367 bp upstream), and 4 Sp1 binding 
motifs (54 bp and 43 bp upstream and 59 bp and 65 bp downstream of the start site) are 
located in the TG2 promoter. TG2 expression is tightly regulated by various external signals 
including retinoids, vitamin D, IL-6, TGF-β1, EGF, TNF and transcription factors including 
RAR:RXR, NF-кB, Sp1 and hypoxia inducible factor (HIF).  
The transamidation reactions result in either the formation of isopeptide bonds between acyl-
acceptor and acyl-donor peptides or modification of proteins by the addition of primary 
amines which alters the properties of proteins. Polyamines as substrates can also mediate an 
indirect crosslink formation between polypeptides. When the thioester bond between enzyme 
and acyl donor peptide is attacked by a water molecule then the reaction is called deamination 
that results in the conversion of the acyl-donor glutamine residue to a glutamate residue. TG2 
activity is tightly regulated under physiological conditions by interaction with cofactors. It can 
bind up to six Ca
2+
 which keep the enzme in open conformation and expose the catalytic core 
domain for the substrate. On the other hand, TG2 contains a unique guanine-binding site 
between the catalytic core and the first β-barrel. GTP/GDP binding leads to considerable 
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interaction between the catalytic domain and two β-barrel domains, which renders TG2 in a 
closed conformation and results in the inhibition of its activity. In its GTP/GDP bound form 
TG2 was shown to act as a G protein in α1 adrenergic receptor signaling, carrying the signal 
to phospholipase C-δ1. Additionally, TPα thromboxane A2 receptor and oxytocin receptor 
were also implicated to exploit TG2 as a G-protein. 
TG2 inside living cells is believed to be predominantly in catalytically-inactive GDP/GTP 
bound form due to the low Ca2+ concentrations. Interestingly, extracellular TG2 was shown 
to be inactive despite high calcium and low GTP levels. In the extracellular environment, TG2 
is present in two different states including oxidized (inactive) and reduced (active) forms. The 
triad of cystein residues including Cys370, Cys371, and Cys230, have very high redox 
potential and oxidizing conditions lead to the formation of interstrand disulfide bonds 
between these residues which in turn inactivate the transamidation activity of TG2. 
In addition to its transamidation and GTPase functions, TG2 has been reported to exhibit 
protein kinase acitivity and be able to phosphorylate insulin-like growth factor-binding 
protein-3 (IGFBP-3), histones, p53 and retinoblastoma protein. Weak phosphorylation of 
TG2-cross-linked IGFBP-3 polymers in the presence of Ca2+ revealed that protein kinase 
activity of TG2 was inhibited by Ca
2+
.  Surprisingly, an inhibitor of the TG2 transamidating 
function, cystamine, was also able to block its protein kinase activity. TG2 itself appeared 
phosphorylated by protein kinase A (PKA) resulting in reduced transamidating activity but 
increased kinase activity of the protein. It was also reported in several studies that TG2 can 
function as protein disulfide isomerase. In one of these studies, denatured RNAse A was 
converted into active enzyme by TG2 through the formation of correct disulfide bonds. It was 
revealed that PDI activity of TG2 is independent from its transamidation activity and is not 
affected by the presence of calcium and nucleotides. Mitochondrial complex I, II and V and a 
mitochondrial protein, the adenine nucleotide translocator 1 (ANT1) are the other proteins 
which were suggested to be substrates for PDI activity of TG2. 
TG2 is also involved in various non-enzymatic functions which are dependent on direct 
noncovalent interactions of this protein with a number of interacting partners localized in 
different cell compartments. These interactions implicate TG2 in a plethora of 
adapter/signaling functions both inside and outside of cells. So far, various TG2 interacting 
partners have been identified and their contribution in TG2 related pathological and 
physiological processes have been well documented. TG2 is able to promote cell-matrix 
adhesion, cell migration, and signaling through its interaction with fibronectin in ECM. TG2 
binds with high affinity to the gelatin-binding region of fibronectin via its N-terminal β-
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sandwich domain. Cell surface TG2 was also found to collaborate with integrins (β1/β3/β5) in 
cell adhesion via both the first and fourth domains of the protein. TG2 serves as a bridge 
between integrins and fibronectin and enhances the interaction of cells with fibronectin. It was 
reported that TG2 also has a strong affinity for another ECM protein, heparin (heparan sulfate 
proteoglycan) and this binding does not affect the catalytic activity of TG2 but protects it 
from thermal unfolding and proteolytic degradation. Cell-surface HS was also implicated to 
be essential in TG2-mediated RGD-independent cell adhesion. HSPGs are divided into 3 
subfamilies; the membrane-spanning proteoglycans (namely syndecans, betaglycan and 
CD44v3), the glycophosphatidylinositol (GPI)-linked proteoglycans (namely glypicans), and 
the secreted extracellular matrix (ECM) proteoglycans (namely agrin, collagen XVIII and 
perlecan) and are major components of extracellular matrices. Among the subfamilies of 
HSPGs, syndecan-4 (S4) is a possible candidate receptor for TG2 in cell adhesion and 
migration. Furthermore, TG2 has been reported to interact with several other proteins inside 
the cells including Bcr and Abr, Angiocidin, PLC δ1, Calreticulin, Importin α3, HIF1β, 
Calmodulin, Bax and Bak. All of these proteins listed above could bind to either an open (e.g., 
Bcr and Abr) or closed (e.g., calreticulin) form of TG2. The bioinformatic analysis to 
determine the role of unique structural features on TG2 function revealed several intrinsically 
disordered (ID) regions along with short linear motifs (SLiMs) in the TG2 sequence. Some of 
the interacting protein binding sites overlapped these ID regions indicating the importance of 
these regions in mediating additional protein–protein interaction and its role in regulating 
diverse protein functions. 
 
1.2. Molecular chaperons 
Molecular chaperons are essential group of proteins in the cells working as guardians of 
protein homeostasis. These proteins are involved in several key cellular functions such as 
protein folding, unfolding, translation, translocation, and degradation under both 
physiological and stressful conditions. In addition to these functions, most chaperones also 
participate in the regulation of protein conformation and stability, protein transport and 
protein–protein interactions. The heat shock proteins (HSP) are the largest and most well-
described group of molecular chaperones. HSP classes include the well-characterized HSP90 
(HSPC) and HSP70 families (HSPA), and the less-well studied HSP40 group (DNAJ) which 
has the greatest number of members. Most chaperones do not work alone and their function is 
mediated by chaperone-regulating proteins known as co-chaperones. These proteins either 
stimulate the chaperons or recruit other chaperons into functional multi-chaperon complexes. 
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1.3. The DNAJ/HSP40 family 
DNAJ family of proteins is the largest and most diverse group of co-chaperons. In humans, 
DNAJ family consists of 49 members and is categorized into three subclasses including type I 
(DNAJA), type II (DNAJB) and type III (DNAJC). Type I DNAJ (DNAJA, 4 members) 
similar to E. coli DnaJ, is composed of an N-terminal J-domain, a glycine/phenylalanine 
(G/F) rich region, a cysteine repeat region and a largely uncharacterized C-terminus. Type II 
DNAJ (DNAJB, 13 members) lacks the cysteine repeat region and consists of the other 3 
domains. However, Type III DNAJ (DNAJC, 32 members) lack both the G/F and Cys-repeat 
regions and the J-domain might be positioned anywhere along the protein. The 70 amino acid 
J-domain is highly conserved across all organisms and pivotal for the interaction with, and 
stimulation, of the molecular chaperone HSP70. Highly conserved histidine–proline–aspartic 
acid [HPD] motif of J-domain is essential for the stimulation of ATP hydrolysis of HSP70. 
The G/F rich region is also thought to support the interaction between the J-domain and the 
ATPase domain of HSP70 facilitating the formation of a stable chaperone complex. However, 
G/F rich region is not essential for stimulation of HSP70, as the selected type III DNAJ 
(DNAJC) which lacks the G/F rich region can also stimulate ATP hydrolysis. The Cys-repeat 
region, also known as the Zinc finger, forms part of the substrate binding domain of DNAJ 
and is important for the presentation of peptides to HSP70. This domain consists of Cys-X-X-
Cys motif repeated four times, where X represents any amino acid. By this way and 
particularly due to the presence of 49 DNAJ and only 13 HSP70s, DNAJ can modulate the 
specificity of HSP70 action on different client substrates. Although the C-terminal region of 
the DNAJ family takes part in the substrate binding domain of type I and II DNAJ and is 
important for efficient co-chaperone functioning, it remains largely uncharacterized. Some 
DnaJ family members contain additional domains which may contribute to their functional 
diversity. For example, the protein disulfide isomerase-like domain of the mammalian DnaJ 
protein ERdj5/JPD1 promotes the formation of appropriate disulfide bonds of endoplasmic 
reticulum (ER) proteins. 
 
Human protein DnaJ subfamily A member 1 (DNAJA1).  
Some of the members of DNAJ family including DNAJA1A, DNAJB1, DNAJB6b and 
DNAJB8 may work as chaperons and suppress the aggregation of client proteins 
independently of HSP70. In addition, DNAJA1 has been indicated to regulate androgen 
receptor signaling and spermatogenesis in mice, and to contribute to the radioresistance of 
glioblastomas. Genomics analysis of pancreatic cancer cells has revealed that DNAJA1 was 
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downregulated 5-fold in these cells relative to normal healthy cells and cells undergoing 
pancreatitis. In another study, overexpression of DNAJA1 resulted in the suppression of the 
stress response capabilities of the oncogenic transcription factor, c-Jun, and the decrease in 
cell survival. Additionally, DNAJA1 seems to play role in importing proteins into the 
mitochondria. 
 
 
2. AIMS OF THE STUDIES 
 
 Characterization and comparison of transamidation activities and calcium sensitivities 
of TG2 Val “wild type” and TG2 Gly “artificial” variants of transglutaminase 2. 
 Identification of novel interacting partners of human TG2. 
 Confirmation of DNAJA1 as a novel interacting partner of human TG2. 
 Determination of the DNAJA1 binding domain of TG2. 
 Determination of DNAJA1 binding conformer of TG2. 
 Identification of the role of DNAJA1 on in vitro and in situ crosslinking activity of 
TG2. 
 To explore if DNAJA1 is a substrate of TG2. 
 
 
3. MATERIAL AND METHODS  
Preparation and analysis of recombinant proteins. Human TG2 was cloned into pET 30 
EK/LIC (Novagen) and pTRIEX 4 Neo mammalian expression vectors (Novagen) and 
DNAJA1 cDNA was subcloned into pET 30 EK/LIC via ligation independent cloning 
according to manufacturers’ protocol. Recombinant TG2 and DNAJA1 were expressed in 
Rosetta 2 E. coli cells (Novagen) by standard protocol. The cells were then collected by 
centrifugation at 4°C and lysed by sonication in 50 ml of lysis buffer [binding buffer (50 mM 
Tris/HCl, pH 7.5, 150 mM NaCl, 5 mM ß-mercaptoethanol, 5 % glycerol, 5 mM imidazole), 1 
mM PMSF, protease inhibitor cocktail tablets (Roche)]. The cells were further lysed by 
adding 1 % Triton-X100 into lysis buffer and  incubating the lysate at 4
 o
C for 30 min and 
then centrifuged at 20,000 x g for 30 min. Clear supernatant was incubated with HisPurTm 
Ni-NTA metal-affinity resin (Thermo Scientific) for 2 hours at 4
 o
C. Resins were washed 
several times with buffer A (binding buffer + 150 mM NaCl) and buffer B (binding buffer + 
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15 mM imidazole). Protein was eluted with buffer C (binding buffer + 250 mM imidazole). 
The purity of the protein was determined by staining of SDS polyacrylamide gels with Page 
blue protein staining solution (Thermo Scientific). For western blots, CUB7402 antibody for 
TG2 (1:2000) (ThermoFisher), MA5-12745 antibody for DNAJA1 (1:1000) and secondary 
antibody, horseradish peroxidase (HRP) conjugated anti mouse IgG (Covalab) (1:10.000) 
were used. Full length and domain deleted variants of TG2 in pGEX 2T vector (GE 
Healthcare) were available in the lab. The constructs were expressed in Rosetta 2 DE3 E. coli 
cells (Novagen). The cells were induced at 25
oC with 100 µM isopropyl β-D-thiogalactoside 
(IPTG) for 6 hours. Cell lysis was performed as described above using binding buffer (50 mM 
Tris/HCl, pH 7.5, 150 mM NaCl, 1 mM DTT, 1 mM EDTA, 5% glycerol) and supernatant 
was incubated with Pierce Glutathione Superflow Agarose Resin (Thermo scientific) for 2 hr 
at 4
o
C. After 2 washes with binding buffer (without glycerol), fractions were collected with 
the binding buffer containing 10 mM reduced L-Glutathione (Sigma) and analysed via SDS 
PAGE.  
Cell culture. General cell culture reagents were purchased from Sigma unless otherwise 
stated. Human embryonic kidney cells (HEK 293T AD) (Agilent Technologies, US) were 
cultured in DMEM and NB4 cells (DSMZ GmbH) were cultured in RPMI-1640 medium 
supplemented with 10% fetal calf serum (Sigma and GIBCO® life technologies, 
respectively), L-glutamine and  penicillin/streptomycin antibiotics. Cells were grown in 5% 
CO2 containing humidified atmosphere at 37
o
C. Generation of stable cell lines of HEK 293T 
AD cells overexpressing human TG2 were carried out using Lipofectamine® 2000 
(Invitrogen). For the downregulation of DNAJA1, TG2 overexpressing HEK 293T AD cells 
were transfected with DNAJA1 specific Silencer Select Pre-designed siRNA (Ambion) using 
Lipofectamine® 2000 (Invitrogen) and scrambled RNA transfected cells were used as control. 
NB4 cells were differentiated for 72 hours by adding 1 µM all trans retinoic acid (ATRA) 
(Sigma, R2625) to express endogenous TG2. These differentiated cells were used for 
experimental analysis. 
GST Pull-Down Assay. Differentiated NB4 cells were used for GST pull down experiment. 
Firstly, the cells were collected and washed in PBS and then resuspended in lysis buffer (50 
mM Tris/HCl, 150 mM NaCl, 1 mM DTT, 1 mM EDTA, 1 mM PMSF, 0.5 % Triton and 
protease inhibitor cocktail). Cells were incubated in lysis buffer for 30 min at 4
o
C and then 
centrifuged at 10,000 g for 20 min. Bradford assay was performed to estimate the clear lysate 
and 1 mg/ml lysate was taken for GST Pull down experiments. Pierce Glutathione Superflow 
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Agarose Resin (Thermo scientific) were washed in RPMI medium and incubated with cell 
lysate and 100 μg of purified recombinant GST tagged TG2 for 1 hour. Equal amount of GST 
was used as a control. Later, the beads were washed 4-5 times with 1 ml of lysis buffer and 
then boiled in laemli sample buffer and loaded on SDS PAGE. Immunoblotting was also 
performed with the same samples and DNAJA1 was detected using anti-DNAJA1 antibody 
(ThermoFisher, MA5-12745). Recombinant purified GST-TG2 and DNAJA1 were also used 
for GST Pull down experiment. Equal amount of GST-TG2/GST and DNAJA1 (100 μg) were 
combined in a single Eppendorf tube with glutathione beads and left for interaction for 1 hour 
at 4
o
C. Rest procedure was the same as described above. 
Mass Spectrometry (LS MS/MS).  GST pull down assay samples were given for mass 
spectrometry analysis. Only those protein bands which were unique to TG2 pulled down 
samples compared to GST control were excised from the SDS PAGE. The gel slices were in-
gel digested with trypsin. During digestion first a reduction was performed using DTT 
followed by alkylation with iodoacetamide (Bio-Rad). The overnight trypsinization was 
performed using stabilized MS grade bovine trypsin (ABSciex) at room temperature and the 
digested peptides were extracted and lyophilized. The peptides were redissolved in 10 µl 1 % 
formic acid and used for LC-MS/MS analysis. 4 µl of sample was used in each case for mass 
spectrometry analysis. 4000 Q TRAP (ABSCiex) - nanoHPLC (Bruker) LC-MS/MS System 
was used for data acquisition. Prior to mass spectrometry analysis the peptides were separated 
using a 90 min. water/acetonitril gradient and 300 nl/min flow rate on an EasynLC II (Bruker) 
nano HPLC. The separation was done on a reverse phase Zorbax 300SB-C18 analytical 
column (Agilent). In order to eliminate the carryover wash steps were administrated after each 
sample. The aquired LC-MS/MS data were used for protein identification with the help of 
ProteinPilot 4.0 (ABSciex) search engine searching the SwissProt database and using the 
Biological modification table included in the ProteinPilot 4.0. The proteomic analyses were 
done in the Proteomics Core Facility, University of Debrecen. 
Nondenaturing polyacrylamide gel electrophoresis. Recombinant His-TG2 and active site 
mutant of His-TG2 (TG2 C277S) were incubated in reaction buffers (50 mM Tris/HCl pH 
7.4, 150 mM NaCl and 0.1 % Tween 20) including EDTA, CaCl2, Z-DON (zedira), CaCl2 + 
Z-DON or GTP for overnight at 4
o
C. Nondenaturing electrophoresis was carried out in 8 % 
polyacrylamide gel in 25 mM Tris and 192 mM glycin including buffer pH 8.3, for 2 hours at 
4
o
C at 40 milliamper and different conformers of TG2 were visualized by Page blue protein 
staining solution (Thermo Scientific). 
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ELISA. The ELISA measurements were performed in triplicates according to standard 
protocol. Interaction of His-DNAJA1 with full length GST-TG2 and domain deleted variants 
of TG2 (GST-TG2Δβ-barrel1 and GST-TG2Δβ-barrel2, GST-TG2ΔCAT, GST-TG2Δβ-
sandwich, GST-CAT) were analysed. Briefly, TG2 and domain variants (1 μg) diluted in 
coating buffer (50 mM Tris/HCl pH 7.5, 150 mM NaCl, 5 mM EGTA, 5 mM EDTA) were 
used to coat the wells of Maxisorp (Nunc) microtiter plate for overnight at 4
o
C and wells were 
blocked with 5 % (w/v) milk powder in TBS-T (0.05 M Tris/HCl pH 7.5, 0.15 M NaCl, 0.01 
M EDTA, 0.1 % Tween 20) for 1 hour at room temperature. The plate was then incubated 
with 0.5 μg DNAJA1 in TBS-T including 5 mM CaCl2 for 1 hour at RT and binding was 
detected with an anti-DNAJA1 monoclonal antibody (ThermoFisher, MA5-12745) diluted 
(1:1000) in TBS-T for 1 hour at RT. After 3 washes, wells were incubated with HRP 
conjugated anti mouse IgG (Covalab) (1:5000) in TBS-T and reaction was detected by adding 
3,3’,5,5’-tetramethylbenzidine and measuring the absorbance at 450 nm. GST coated wells 
were used to measure nonspecific binding and subtracted from the values observed in the TG2 
and domain variants coated wells.  
Surface plasmon resonance measurements. Surface plasmon resonance (SPR) 
measurements were performed in a Biacore 3000 instrument (Biacore, Uppsala, Sweden). 
Binding assays were performed at 25
o
C. Anti-GST antibody (Biacore™, GE Healthcare) was 
immobilized on sensor chip CM5 (BR-1000-12; Biacore™, GE Healthcare) using the amine 
coupling method as recommended by the manufacturer. Surface activation was performed by 
an injection of 35 μl EDC/NHS solution (200 mM EDC and 50 mM NHS). The anti-GST 
antibody was diluted to 30 μg/ml in 10 mM Na-acetate (pH 5.0) (immobilization buffer) and 
injected over the surface for 7 min at 5 μl/min flow rate. Excess reactive sites were 
subsequently blocked by injection of 1 M ethanolamine (pH 8.5). On the sensor chip surfaces 
full-length GST-TG2 and GST tagged domain variants of TG2 (GST-TG2Δβ-barrel1 and 
GST-TG2Δβ-barrel2, GST-TG2ΔCAT, GST-TG2Δβ-sandwich, GST-CAT) were 
immobilized in running buffer containing 50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1mM 
EDTA and recombinant GST was used as reference. The immobilization level of GST-fusion 
proteins was 500-1000 RU according to their molecular weight. The various concentrations of 
DNAJA1 protein were injected over the control and the different TG2 variants coated 
surfaces. After each binding analysis, the sensor surfaces were regenerated and the sensor 
surfaces were recoated with fresh protein solutions for the next binding studies. The 
11 
 
evaluation of the sensorgrams was carried out with BIAevaluation 3.1 software (Biacore 
3000). 
Immunocytochemistry. Co-immunostaining experiments were performed to determine the 
localization of TG2 and DNAJA1 in TG2 overexpressing HEK 293T AD cells. Firstly, the 
cells were cultured on glass coverslips and fixed with 4 % PFA for 15 min at 25
o
C. After that, 
the cells were treated with NH4Cl-PBS for 10 min at 25
o
C to quench free aldehyde groups and 
permeabilized with 0.1 % Triton-X 100 for 10 min at 25
o
C. After washing with PBS-T 
(phosphate buffered saline, pH 7.4, with 0.1 % Tween-20), they were blocked first with 5 % 
goat serum in PBS-T for 30 min and with 5 % milk powder for 1 hour at 25
o
C. The coverslips 
were then incubated with anti TG2 (1:500, polyclonal rabbit IgG, Santa Cruz Biotechnology) 
and anti DNAJA1 antibody (1:500, monoclonal mouse IgG, ThermoFisher, MA5-12745) in 5 
% goat serum in PBS-T for 2 hours at RT. They were blocked once more with 5 % goat serum 
for 10 min and treated with secondary goat antibodies coupled to Alexa Fluor® 488 (anti 
mouse IgG) and Alexa Fluor® 568 (anti rabbit IgG ) (1:5000) in 5 % goat serum. The nuclei 
were stained by DRAQ5 (1:1000). Finally, the coverslips were mounted with DAPCO-
Mowiol (1:50) and visualized by confocal microscopy (Olympus FluoView FV1000). 
TG2 activity assays. To compare the transamidation activities of TG2 glycine224 and 
valine224 variants, kinetic spectrophotometric UV assay was used. Briefly, the deamidation 
of a glutamine substrate releasing ammonia was measured. Microtiter plate assay, based on 
the incorporation of 5-(biotinamido) pentylamine (BPA) into immobilized N,N-dimethylated 
casein was used as described before by Slaughter et al. This assay was used for comparison of 
TG2 glycine224 and valine224 activities and also to determine the role of DNAJA1 on TG2 
valine224 activity. Briefly, Maxisorp  (Nunc) microtiter plate was coated with 1 mg/ml N,N-
dimethylated casein (DMC; Sigma) in coating buffer (50 mM Tris/HCl pH 7.5, 150 mM 
NaCl, 5 mM EGTA, 5 mM EDTA) overnight at 4
 o
C and washed twice with PBS-T 
(phosphate buffered saline with 0.1% tween-20) pH 7.4. Wells were then blocked with 5 % 
(w/v) milk powder in PBS-T for 1 hour at RT. After washing with PBS-T, the reaction 
mixture including 0.1 M Tris/HCl pH 7.5,  1 mM BPA (5-(Biotinamido)pentylamine), 1 mM 
DTT, 5 mM CaCl2, 1 μg recombinant His-TG2 (to detect the effect of DNAJA1, different 
concentrations (0.2-1 μg) were added along with TG2) were added to the wells and incubated 
for 30 minutes at 37
 o
C. Subsequently, streptavidin-alkaline phosphatase in PBS-T was added 
to each well and incubated for 1 hour at 25
o
C. After adding the substrate solution (p-
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nitrophenyl phosphate), BPA incorporation was quantitated measuring the absorbance at 405 
nm in ELISA microplate reader.  
In kinetic assay, incorporation of monodansylcadaverine (Dansyl-Cd, a fluorometric-labeled 
cadaverine) (Sigma) into DMC (N,N-dimethylated casein) was measured. The reaction 
mixture comprised 50 mM Tris/HCl pH 7.5, 0.2 mM Dansyl-Cd, 16 μM DMC, 1 mM DTT, 5 
mM CaCl2, and 100 nM His-TG2 with or without 3 μM DNAJA1. The reaction mixture was 
incubated at 37
 o
C for 60 minutes. The increase in flourescence intensity was followed using 
BioTek Synergy H1 Multi-Mode Reader (Bio Tek US; Ex/Em: 360/530 nm). In situ TG2 
activity assay was performed as described previously by Zhang et al with some modifications. 
The HEK 293T AD cells overexpressing TG2 (HEK-TG2) were first treated with 1 mM BPA 
for 1 hour and then with calcium ionophore A23187 (Sigma) for 1 hour to activate the TG2. 
The cells were then collected and washed with PBS. The cell pellets were resuspended in lysis 
buffer (50 mM Tris/HCl, 150 mM NaCl, 1 mM DTT, 1 mM EDTA, 1 mM PMSF, 0.5 % 
Triton and protease inhibitor cocktail) and further lysed by sonication. The protein in the 
supernatant was quantified with Bradford. Western blot was performed on the cell lysate with 
streptavidin conjugated HRP and HRP substrate. For quantification, 30 µg of the cell lysate 
was coated to a Maxisorp (Nunc) microtiter plate and then detected as described before. 
Analysis of DNAJA1 as a substrate of TG2. Maxisorp (Nunc) microtiter plate was coated 
with 0.5 μg DNAJA1 and BPA incorporation into DNAJA1 was measured as described above 
in TG2 activity assay. Another confirmation experiment was performed as described by 
Ruoppolo et al. Recombinant His-TG2 (0.5 μg) was incubated with various concentrations of 
DNAJA1 (0.1-1 μg) in reaction buffer including 0.1 M Tris/HCl pH 7.5, 1 mM BPA as acyl 
donor, 1 mM DTT and 5 mM CaCl2 for 1 hour at 37
 o
C. The reaction products were directly 
analysed by immunoblotting, using streptavidin peroxidase and the monoclonal antibodies 
against TG2 and DNAJA1.  
Quantitative RT–PCR (qRT–PCR). Trizol reagent was used for the isolation of total RNA. 
Reverse transcription was performed at 25°C for 10 min, 37°C for 2 h and 85°C for 5 min 
from 1μg of total RNA using High Capacity cDNA Reverse Transcription Kit (Thermo Fisher 
Scientific). qPCR was performed in the LightCycler® 480 II (Roche) instrument using 
TaqMan® (Thermo Fisher Scientific) probes for transglutaminases (TG1-7 and FIIIa). 
Thermocycling conditions used for qPCR were 1 cycle (95°C, 10 min), 45 cycles (95°C, 10 s; 
60°C, 8 s; 72°C, 15 s) and 1 cycle (95°C, 1sn; 65°C; 15 s). The comparative Ct method was 
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used to quantify TG transcripts and normalization was performed with the GAPDH 
housekeeping gene. 
Statistical Analysis. Experiments were repeated three times (stated in the figure legend) with 
three parallels and the data reported are as mean ± SEM from the representative experiment. 
Statistical significance was determined by two tailed paired Student t test (parametric) by 
using Graph Pad Prism version 5.0. The p ≤ 0.05 value was considered significant. 
 
4. RESULTS 
4.1. Characterization and comparison of transamidation activity and calcium sensitivity 
of Gly224 and Val224 variants.  
4.1.1. Valine 224 strongly influences transamidation activity of TG2 at low Ca2+ 
concentrations 
We investigated the biochemical and structural characteristics of the TG2 Val variant and 
compared them to those of TG2 Gly. We analysed the transamidation activities of these 
variants and observed that TG2 Val showed 20% increase in transamidase activity compared 
to TG2 Gly variant when microtiter plate or radioactive assays were used. Since both these 
assays were end point measurements we resorted to kinetic assays to monitor real time 
activities. Using kinetic UV-test, TG2 Val showed ten-fold higher transamidase activity as 
compared to TG2 Gly at low Ca2+ concentrations. The activity difference between the two 
variants decreased with increasing Ca2+ concentration but did not disappear. This suggests 
that the Ca2+ sensitivity deviates in the two variants. Indeed, EC50 values for Ca2+-
dependence / sensitivity in case of transamidase activities were 0.36 ± 0.18 mM for TG2 Val 
and 2 ± 0.14 for TG2 Gly, respectively, indicating a higher binding affinity for Ca2+ for TG2 
Val as compared to TG2 Gly. 
4.1.2. Effect of V224 on transamidation activity of TG2 in cells  
To eliminate confounding factors due to expression of human TG2 in bacterial cells, the 
activity measurements were repeated using HEK 293T cell lysate overexpressing TG2 
variants. In accord to the results obtained by enzymes produced in E.coli, TG2 Val showed a 
higher transamidation activity than TG2 Gly. 
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Since in vitro results showed a clear difference in the biochemical properties of the two 
enzyme variants, we further wanted to confirm the results via cellular assays. We used BPA, a 
cell permeable amine substrate for transglutaminases, to determine the in situ TG2 activity in 
293T AD cells stably transfected with the TG2 variants. Untransfected cells showed no 
crosslinking activity either with or without BPA. Cells transfected with TG2 Val showed a 
significant increase in incorporation of BPA into intracellular proteins while TG2 Gly showed 
a negligible increase when compared to control. On treating the samples with calcium 
ionophores, which had been used previously to activate TG2 in cells, both variants showed an 
increase in crosslinking activity. However, this increase was much more pronounced in case 
of TG2 Val compared to TG2 Gly. The crosslinking activity could be inhibited when the cells 
were pre-incubated with 100 μM of TG2 active site inhibitor ZDON confirming the TG2 
specific reaction. The expression levels of TG2 were identical in all the samples confirming 
that the difference in activity was not due to different amounts of TG2. Both Western blot and 
ELISA were used for visualizing the crosslinking reaction but Western blot was more 
sensitive in detecting the difference in TG2 activities with TG2 Val containing cells 
consistently showing higher transamidation activity compared to TG2 Gly transfected cells. 
4.2. DNAJA1 as a novel interacting partner of transglutaminase 2 
4.2.1. Screening of TG2 interacting proteins in differentiated NB4 cells  
TG2 interacting proteins play a very crucial role in modulating TG2 functions. It is well 
documented that the same interacting partner can modulate TG2 functions inversely 
depending upon its cellular location. Therefore we have mainly focused on identifying novel 
interacting partners of TG2 using human promyelocytic leukemia cell line (NB4). NB4 cell 
line upon differentiation with all trans retinoic acid (ATRA) expresses a very high level of 
TG2, which leads to a massive upregulation of genes involved in many physiological and 
pathological processes. Knocking down TG2 in ATRA treated NB4 cells leads to 
downregulation of the above reported genes. Therefore NB4 cells were considered as an 
excellent cell model to explore TG2 interacting partners and the related functions they 
modulate. Secondly, this cell line has also never been used before for such kind of studies 
making it an attractive model for our analysis. GST Pull down experiments and subsequent 
mass spectrometry analysis of differentiated NB4 cells lead to identification of human 
Glutathione S Transferase (hGST-P1), Tubulin α, Histone H2A and DNAJA1 as potential 
binding partners of TG2. Since all of the above proteins except DNAJA1 have already been 
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reported either to interact with TG2 or is a substrate of TG2 therefore DNAJA1 was 
considered as a novel interacting protein. Mass spectrometry identified peptides of DNAJA1 
with 90 % confidence. We confirmed the specific interaction by using anti-DNAJA1 antibody 
on GST Pull down samples. Further we expressed and purified recombinant TG2 and 
DNAJA1 and performed GST Pull down experiments to confirm their direct interaction. 
4.2.2. TG2 directly interacts with DNAJA1 mainly through its catalytic domain  
Physical interaction of TG2 with DNAJA1 was confirmed via ELISA and SPR measurements. 
Domain deleted variants of TG2 were also used in these experiments to determine DNAJA1 
binding domain of TG2. In both assays, we observed that TG2-DNAJA1 interaction increased 
with higher concentrations of DNAJA1. The results demonstrate that DNAJA1 interacts with 
full length TG2 and domain variants of TG2 including GST-TG2Δβ-barrel2, GST-CAT, 
GST-TG2Δβ-sandwich, GST-TG2Δβ-barrel1 and GST-TG2ΔCAT. Highest binding affinity 
for DNAJA1 was observed with GST-TG2Δβ-barrel2 whereas GST-TG2ΔCAT variant 
showed the least interaction with DNAJA1 suggesting that catalytic domain of TG2 is 
essential for TG2-DNAJA1 interaction and β sandwich domain together with β barrel 1 
domain further improve this interaction. 
4.2.3. DNAJA1 interacts with the open conformer of TG2  
TG2 mainly adopts two different conformations depending on the type of binding effectors. In 
agreement with earlier reports, electrophoresis under non-denaturing conditions revealed that 
recombinant human TG2 produced in E.coli adopts an open conformation in the presence of 
Ca
2+ 
whereas GTP induces a closed conformation. Since TG2 undergoes self-crosslinking in 
the presence of calcium, we have treated TG2 with ZDON (referred to as iTG2), which binds 
irreversibly to the cysteine present in the active site of TG2 thereby inhibiting its crosslinking 
activity. We also checked TG2 conformer in the presence of EDTA, which was used to 
remove residual calcium from the bacterial expression system. However, instead of observing 
a closed conformation, majority of TG2 existed in open conformation in the presence of 
EDTA. This is most likely because TG2 binds very strongly to the calcium present in the 
bacterial cell lysate and by mere addition of EDTA was not enough to chelate / dissociate this 
bound calcium from TG2. Also, there are probably some effectors derived from expression 
system that help in keeping the TG2 in open conformation and was not completely removed 
during the purification and by the addition of EDTA either. To explore whether DNAJA1 
binds to the open or closed form of TG2 we performed interaction studies via ELISA in the 
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presence of aforementioned effectors. TG2-DNAJA1 interaction was significantly higher in 
the presence of EDTA or Ca
2+ 
in combination with Z-DON compared to GTP including 
conditions which suggest that DNAJA1 interacts mainly with the open conformer of TG2. 
DNAJA1 also showed interaction with transamidation inactive mutant of TG2 (TG2 C277S), 
which indicates that TG2-DNAJA1 interaction is not dependent on crosslinking activity of 
TG2. 
4.2.4. DNAJA1 facilitates and stabilizes in vitro crosslinking activity of TG2 
To explore the significance of TG2-DNAJA1 interaction, we firstly wanted to determine the 
effect of DNAJA1 on crosslinking activity of TG2. BPA incorporation into surface bound 
glutamine donor substrate N,N-dimethylated casein (DMC) by TG2 in an endpoint assay was 
higher in the presence of DNAJA1 as compared to control. The amount of crosslinked product 
was further increased with higher DNAJA1 concentrations. This indicated that DNAJA1 
either modulated or stabilized the crosslinking activity of TG2 in vitro. Kinetic measurement 
of Dansyl-cadaverine incorporation into DMC by TG2 in the presence of DNAJA1 in a fluid 
phase system didn’t show any effect on TG2 crosslinking activity when the measurements 
were taken until first 25 min. Nevertheless, after 30 – 60 min an increase in transamidation 
activity of TG2 was observed. However, this increase in activity had a p value greater than 
0.05. The kinetic parameters of TG2 for DMC substrate in the presence and absence of 
DNAJA1 were estimated by Michaelis Menten and Lineweaver-Burk plots. Km was 
calculated  as 17.6 μM, Vmax as 8.9 µM/min and Kcat as 90 min-1 for TG2 without DNAJA1. 
In the presence of DNAJA1 we observed a decrease in Km value, which was calculated as 13 
μM, Vmax as 8 µM/min and Kcat value as 78 min-1. These results suggest that DNAJA1 
increases the substrate affinity of TG2 thereby increasing its enzymatic activity as observed in 
the endpoint activity measurements and later half of the kinetic activity measurements. 
4.2.5. Downregulation of DNAJA1 results in increased BPA incorporation in TG2 
overexpressing HEK cells  
To confirm the role of DNAJA1 on crosslinking activity of TG2, we further performed 
cellular experiments wherein we used BPA, a cell permeable amine substrate for 
transglutaminases, to determine the in situ TG2 activity in DNAJA1 downregulated HEK 
cells stably transfected with human TG2 (HEK-TG2). DNAJA1 siRNA were used to 
knockdown the expression of DNAJA1 and scrambled RNA transfected and untransfected 
cells were used as control. Downregulation of DNAJA1 was demonstrated via Western blot. 
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Both ELISA and Western blot were performed to visualize the crosslinking reaction initiated 
by adding Ca
2+
-ionophore to the cells. The results indicated surprisingly that there was a 
significant increase in crosslinking activity of TG2 in cells with downregulated DNAJA1 
compared to the controls. We also used TG2 un-transfected HEK cells and there was no 
crosslinking activity in these cells. In our previous study, it was also demonstrated that 100 
μM of TG2 active site inhibitor Z-DON could inhibit the crosslinking activity in HEK-TG2 
cells confirming the TG2 specific reaction. These results suggest that DNAJA1 has the ability 
to regulate the crosslinking activity of TG2 in the cells. To ascertain whether downregulation 
of DNAJA1 has any impact on the expression of TG2 in HEK-TG2 cells, Western blot was 
carried out and there was no difference in the amount of TG2 protein. To explore the changes 
in the gene expression levels of other transglutaminases upon DNAJA1 downregulation, we 
performed QPCR analysis. None of the other protein members of transglutaminase family 
were expressed in HEK-TG2 either with or without downregulation of DNAJ1.  
4.2.6. Colocalization of TG2 with DNAJA1 in cytoplasm of TG2 overexpressing HEK 
cells 
HEK-TG2 cells were used to determine the localization of TG2 and DNAJA1 in an intact 
mammalian cellular system. Co-localization experiments with NB4 cells were also performed 
but gave very high background therefore HEK-TG2 cells were used for the experiments. Dual 
immunohistochemistry staining of HEK-TG2 cells was performed with anti-TG2 and anti-
DNAJA1 antibodies. Both TG2 and DNAJA1 were observed to localize predominantly in 
cytosolic fraction with low expression in nuclei. Co-localization of TG2 and DNAJA1 in the 
cytosolic region indicates a potential association of the two molecules with physiological 
processes in vivo. 
4.2.7. DNAJA1 is a glutamine donor substrate of TG2 
Since DNAJA1 was found to interact with catalytic core domain of TG2 we speculated that it 
can also serve as a TG2 substrate. To explore this hypothesis, DNAJA1 was incubated with 
the enzyme in the presence of an acyl donor BPA. Reaction products were analysed by 
SDS/PAGE, immunoblotting and ELISA and results showed that BPA was crosslinked to 
DNAJA1. The amount of incorporation was increased with higher concentrations of 
DNAJA1. Incorporation did not occur in the absence of TG2 or calcium confirming that BPA 
incorporation into DNAJA1 is mediated by transamidating activity of TG2. We also 
performed the kinetic transamidation assay replacing dimethylated casein with DNAJA1 and 
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monitored the incorporation of Dansyl-Cd into increasing concentrations of DNAJA1. We 
observed a linear increase in the amount of incorporated Dansyl-Cd at increasing 
concentrations of DNAJA1 confirming that it is a glutamine donor substrate of TG2. 
 
5. DISCUSSION 
The recent publication on the polymorphisms of human TG2 reported that the sequence at the 
position 224 is Valine instead of Glycine in all the known human genomes. During the last 
two decades, artificial variant of TG2 (TG2 224Gly) has been used in various laboratories 
Hence, it was important to first characterize the biochemical and structural relevance of TG2 
Val “wild type” enzyme before working further on TG2 regulated processes. We performed 
several experiments to compare the transamidase activities and calcium sensitivity of these 
TG2 variants and found that TG2 Val shows 10 folds increase in both transamidation activity 
and calcium sensitivity. These results explain why high Ca
2+
 concentration had to be used in 
earlier studies for activation of TG2. According to the previous views, TG2 does not exhibit 
activity inside the cell at physiological conditions due to low calcium concentrations and high 
GTP concentrations, which is inhibitory for transamidation activity of TG2. Therefore, 
calcium ionophores have been used in most cellular experiments to activate TG2. In our 
study, crosslinking activity of TG2 Val was detected in the absence of Ca
2+
-ionophore and it 
could be increased further by adding A23187. All these results suggest that TG2 can be 
activated inside the cells at physiological conditions and therefore reassessment of its 
potential cellular activity should be considered. 
TG2 shows broad substrate specificity and it also non-enzymatically interacts with numerous 
proteins inside and outside the cells which may account for its multiple biological functions. 
For this reason, we have chosen to focus on identification of novel interacting partners of 
human TG2 using NB4 acute promyelocytic leukemia (APL) cell line since treating this cell 
line with all trans retinoic acid (ATRA) results in enhanced expression of TG2 as well as 
massive changes in the expression of other APL genes. We identified a novel intracellular 
interacting partner of human TG2 which is a molecular heat shock protein, namely DNAJA1. 
Previous reports suggest that there are few other heat shock proteins, which binds to TG2 and 
play important roles in various physiological and pathological processes in cooperation with 
TG2. For example, TG2 overexpression upon excitotoxic stress and thereby interaction with 
Hsp20 leads to modulation of anti-apoptotic function of Hsp20/27 complex and reduction in 
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the activity of caspase 3 ultimately protecting the cells from apoptotic damage. TG2 was also 
shown to interact with HSP70 in HELA and MDAMB231 breast carcinoma cell, which 
ultimately regulated cancer cell migration. 
Our finding that DNAJA1 could interact with TG2 opened new avenues to be explored since 
DNAJA1 is not only involved in chaperon activity but it has also been reported to regulate 
several other TG2 mediated cellular functions as described below. DNAJ family of proteins is 
the largest and most diverse family of co-chaperones. These proteins are involved in several 
important cellular functions including the suppression of protein aggregation, folding of 
nascent and damaged proteins, translocation of proteins into cellular compartments and the 
targeting of proteins for degradation. They are widely accepted to work as co-chaperons 
regulating the activity of other chaperons such as HSP70 and HSP90 but they also include 
members which can work independently from these chaperons. In humans, DNAJ family 
consists of 49 members divided into 3 major groups, type I (DNAJA), type II (DNAJB) and 
type III (DNAJC). DNAJ family of proteins has been reported to play important roles in 
several pathological processes such as neurodegenerative disorders and cancer. For example, 
DNAJA1 member of the family has been shown to contribute to the resistance of 
glioblastomas to radiotherapy. Another study revealed that DNAJA1 promotes apoptosis in 
pancreatic cancer cells by suppressing the JNK pathway, the hyper phosphorylation of c-Jun, 
likely activating DnaK (HSP70) protein by forming a complex. As we know that like 
DNAJA1, TG2 is also reported to regulate cancer cell migration, apoptosis and neurological 
disorders, we speculate that DNAJA1 and TG2 might work in collaboration in regulating 
these cellular processes and pathological states.  
When we used different constructs of TG2, each one lacking one or more domains of TG2, 
we observed that DNAJA1 interacts with core domain itself as well as it does with full length 
TG2. However, domain deleted variant lacking core domain shows the least interaction with 
DNAJA1 suggesting that core domain of TG2 is the most important domain in this interaction 
and since core domain has been shown to be catalytically inactive this interaction also 
confirms that catalytic activity of TG2 is not required for TG2-DNAJA1 interaction. 
The role of DNAJA1 on TG2 crosslinking activity was also investigated and we could see an 
increase in the TG2 activity in the end point assay measured via ELISA on increasing 
DNAJA1 concentrations. However, TG2 activity measurements via kinetic assay didn’t show 
any significant increase in enzymatic activity in the early phase of kinetic reaction but some 
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increase was seen in the later stage i.e. after 30-60 min. Statistical analysis on the kinetic 
assay confirmed that the increase in the activity in the later half was non-significant. We also 
determined the kinetic parameters to understand how DNAJA1 regulated TG2 activity. 
Addition of DNAJA1 shifted the Km values of TG2 from 17.6 µM to 13 µM while Vmax 
remained unchanged. Kinetic parameters were calculated only for the first half of the reaction 
i.e until 30 min. During the later half, the reaction was non-linear therefore the kinetic 
parameters could not be calculated. Our results suggest that, DNAJA1 stabilizes the TG2 
active state conformation thereby increasing its substrate specificity and its transamidation 
activity. Though in the early phase of the kinetic measurement we didn’t observe any change 
in the activity, we could observe an increase in the activity in the later half suggesting that 
DNAJA1 stabilizes TG2 active state conformation in longer time period. Surprisingly, in situ 
BPA incorporation assay results indicated that enzyme activity was somehow enhanced in 
DNAJA1 downregulated HEK-TG2 cells compared to scrambled and un-transfected controls. 
There might be several possible explanations for this result. One of the possible reasons could 
be that DNAJA1 interaction keeps the enzyme in a multiple protein complex which together 
masks the catalytic site of TG2 inside cells thereby preventing catalysis. We have shown here 
that DNAJA1 binds to the catalytic domain of TG2 which corroborates with this observation. 
TG2 catalytic site is freely available for substrate binding on downregulating DNAJA1 
therefore enhanced crosslinking activity is seen subsequently. Another possible reason could 
be that, DNAJA1 might compete with other substrates of TG2 and limits its substrate 
specificity since we also found that DNAJA1 is a glutamine donor substrate of TG2. In other 
words, we can conclude that compared to in vitro conditions, the effect of DNAJA1 on TG2 
activity in cells shows difference most likely due to the presence of several other factors. As 
mentioned before, the crosslinking activity of TG2 plays significant roles in several important 
pathological processes and its in vivo inhibition has gained great importance for therapeutic 
treatments of human diseases. Our results therefore suggest that DNAJA1 could be considered 
as an important protein target with therapeutic potential. Since we showed that the 
downregulation of DNAJA1 improves the activity of TG2 in cells, it will be interesting to 
observe whether its overexpression inhibits TG2 activity in normal cells and in different cell 
models of diseases.  
We could successfully identify yet another interacting partner which can interact with TG2 
non-enzymatically as well as also function as a substrate. Other proteins which have been 
reported to have such dual functions include fibronectin, BCR, Angiocidin and 
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Retinoblastoma. As mentioned before, DNAJ family of proteins and particularly DNAJA1 
play important roles in certain types of cancer and neurodegeneration and since TG2 is also 
involved in these processes, it will be interesting to see whether DNAJA1 and TG2 interaction 
regulates these pathological conditions. We already performed several cell migration assays 
using differentiated NB4 cells and we downregulated TG2 and also DNAJA1 and compared 
the migration of these cells to un-transfected controls. Using these cells we could not detect 
any difference in cell migration between TG2 KD and un-transfected cells and also DNAJA1 
downregulated cells showed the similar result compared to un-transfected NB4 cells. Our 
future attempt will be to explore the significance of TG2-DNAJA1 interaction via using 
different cancer and neurological cell models.  
 
6. SUMMARY 
Transglutaminase 2 (TG2) is a multifunctional enzyme which participates in posttranslational 
modification of proteins, such as catalyzing calcium dependent crosslinking of proteins, 
incorporation of primary amines and deamidation of proteins. In addition, TG2 also acts as a 
G protein, has protein disulfide isomerase, protein kinase activities and plays non-enzymatic 
roles such as functioning as an adaptor protein, cell surface adhesion mediator and forming 
protein scaffolds. In our study, we first compared the transamidation activity and calcium 
sensitivities of Gly224 and Val224 variants of TG2 and found that the Val variant, which is 
the actual wild type variant in the human genome, exhibits significantly higher activity and 
calcium sensitivity compared to Gly variant which was used in many previous studies in other 
laboratories. In the rest of the project we used Val224 “wild type” variant of TG2.  
Our main aim in this study was to identify the novel interacting partners of human TG2. For 
this aim, we used NB4 promyelocytic leukemia (APL) cell line which overexpresses TG2 and 
also other APL related genes upon differentiation by ATRA. Among several other interacting 
partners, we identified DNAJA1 as a novel interacting partner of TG2. We further confirmed 
this interaction via several in vitro experiments such as ELISA and SPR measurements. The 
same experiments were performed to determine the DNAJA1 binding domain of TG2 and 
results suggested that core domain of TG2 is the essential domain for TG2-DNAJA1 
interaction. Furthermore, DNAJA1 was found to interact mainly with open conformer of TG2. 
To explore the effect of DNAJA1 on crosslinking activity of TG2 we carried out some in vitro 
and in situ experiments and observed that DNAJA1 inversely regulates the activity of TG2. 
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Moreover, DNAJA1 was also identified as a novel substrate of TG2. DNAJA1 and TG2 have 
been independently reported to regulate similar cellular and pathological processes, such as 
cellular transport, apoptosis, neurodegenerative disorders and cancer. We propose that both 
the proteins regulate these overlapping functions via intermolecular interactions. 
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